Pharmaceutical Business review

Teva Reports 33% Rise In Q4 Net Sales

Quarterly non-GAAP net income was $847m, an increase of 28% compared to same period an year ago. Annual non-GAAP net income $3 billion, an increase of 22% compared same period in 2008.

Quarterly non-GAAP operating income was $1.0 billion, up 41% compared with the fourth quarter of 2008. Quarterly GAAP operating income totaled $412m, compared with a loss of $412m.

Teva’s annual non-GAAP operating income was $3.9 billion, up 35%. Annual GAAP operating income totaled $2.4 billion, compared with $1.1 billion.

Shlomo Yanai, president and chief executive officer of Teva, said: “2009 was a very good year for Teva, a year in which our company delivered record-breaking sales and profits across all our geographies and major businesses.

“This was also a year of major strategic achievements, including the successful integration of Barr, a process which was completed less than a year after closing, and from which we expect to continue to derive significant synergies for many years to come.

“I believe that especially against the backdrop of a troubled world economy, our results this year demonstrate Teva’s agility and the strength of our balanced business model, which enable us to deliver continuous profitable growth year after year.”

Exit mobile version